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a  b  s  t  r  a  c  t
ONRAB® is a recombinant  human  adenovirus  type  5 (HAd5)  with  the  rabies  glycoprotein  gene incor-
porated  into  its genome.  ONRAB® has  been  used  in Canada  as  an  oral  rabies  vaccine  in target  wildlife
species  such  as: red  fox  (Vulpes  vulpes),  raccoon  (Procyon  lotor),  and  striped  skunk  (Mepthis  mephitis).  We
evaluated  the safety  of  ONRAB® in non-target  wildlife  species  likely  to  contact  the  vaccine  baits  during
oral  rabies  vaccine  campaigns  in the  United  States.  We  investigated  the  effects  of oral  inoculation  of  high
titer ONRAB®, approximately  ten times  the dose  given  to  target  species,  in wood  rats  (Neotoma  spp.),
eastern  cottontail  rabbits  (Sylvilagus  floridanus),  Virginia  opossums  (Didelphis  virginiana),  eastern  wild
turkeys  (Meleagris  gallopavo  silvestri),  and fox squirrels  (Sciurus  niger).  We  performed  real-time  poly-
merase  chain  reaction  (PCR) on fecal  swabs,  oral  swabs,  and  tissues,  including  lung,  liver,  kidney,  small
intestine,  large  intestine,  and when  appropriate  nasal  turbinates,  to detect  ONRAB® DNA  from  inoculated
animals.  By  seven  days  post-inoculation,  turkeys,  opossums,  and  cottontails  had  all  stopped  shedding
ONRAB® DNA.  One  wood  rat  and  one  fox squirrel  still  had  detectable  levels  of  ONRAB® DNA in fecal
swabs  14  days  post-inoculation.  Real-time  PCR  analysis  of  the tissues  revealed  some  ONRAB® DNA  per-
sisting  in  certain  tissues;  however,  there  were  no  significant  gross  or histologic  lesions  associated  with
ONRAB® in  any  of the  species  studied.  Our results  suggest  that  many  non-target  species  are  not  likely
to  be  impacted  by the  distribution  of  ONRAB® as part  of  oral  rabies  vaccination  programs  in  the  United
States.
Published by Elsevier Ltd.
1. Introduction
Rabies viruses in the United States once affected domestic ani-
mals and wildlife alike, but since the 1970s have been effectively
eliminated in domestic animals, a result of municipal mandates
requiring pets be vaccinated for rabies. Now control of rabies
virus in the United States focuses on controlling the pathogen in
wildlife reservoirs. Since 1995, the United States National Rabies
Management Program (NRMP), administered by the United States
Department of Agriculture, Animal and Plant Health Inspection
Service, Wildlife Services (WS), has been working to control terres-
trial rabies virus through wildlife vaccination. Oral rabies vaccines
are distributed by hand and by fixed and rotary-wing aircraft in
most states east of the Appalachian Mountains, as well as portions
of Ohio, Texas, New Mexico, and Arizona. It is estimated that at least
60% of raccoons (Procyon lotor) in an infected population must be
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immunized against the rabies antigen to eliminate raccoon rabies
[1]. At present, it is estimated that 30% of raccoons are inoculated
[2] by the Oral rabies vaccination (ORV) program in the United
States.
Raboral V-RG® (Merial Ltd., Athens, GA), the vaccine presently
used in the ORV program, is a recombinant vaccine comprised of
a vaccinia virus with the rabies glycoprotein gene inserted into its
genome. Presently, raccoons, gray foxes (Urocyon cinereoargenteus),
coyotes (Canis latrans), and possibly other terrestrial mammals
can be inoculated by ingesting this liquid vaccine, which is con-
tained in a palatable sachet [2,3]. Ideally, when the animal bites
into the sachet the liquid vaccine coats the buccal lining, entering
and replicating in the oral cavity, tonsils, and other surround-
ing tissues, and stimulates an immune response. However, the
immunogenicity of Raboral V-RG, as determined by measurements
of circulating rabies virus neutralizing antibodies (rVNA), is lim-
ited. Brown et al. [4] reported that of 19 wild raccoons inoculated
by Raboral V-RG® 14 succumbed to a rabies challenge. Addition-
ally, a vaccine comparison study in Canada and the United States
found that only 30% of raccoons inoculated in the United States by
Raboral V-RG® demonstrated detectable rVNA ≥0.5 IU/mL, while
nearly 75% of raccoons administered, ONRAB® (Artermis Technolo-
gies, Guelph, Ontario, Canada) produced rVNA titers ≥0.5 IU/mL
[5,6].
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ONRAB® is a recombinant oral rabies vaccine with human
adenovirus type 5 (HAd5) as the backbone and the rabies virus gly-
coprotein gene inserted into its genome. HAd5 is a relatively safe
and well-studied virus, which is used in many vaccine formula-
tions [7–9], but does not replicate well in most non-human species
[10]. The addition of the rabies virus glycoprotein allows the virus
to infect many different species and triggers the host’s immune
system to produce antibodies against the rabies virus [10,11]. Stud-
ies on the efficacy and safety of the ONRAB® vaccine in animals
have been completed in Canada [6,11]. Results of field and labo-
ratory studies indicated that persistence of the virus in animals is
short-lived and that ONRAB® is unlikely to have an overall negative
impact on wildlife [6,10–12]. Rabies virus seroconversion rates for
raccoons in areas baited with ONRAB® averaged 80% in the first two
years [13], well above the seroconversion rates detected when the
vaccine Raboral V-RG® was used [3,4].
Knowles et al. conducted vaccine safety and immunogenic-
ity studies on 18 species: striped skunks, red foxes (V. vulpes),
raccoons, meadow voles (Microtus pennsylvanicus), deer mice (Per-
omyscus leucopus), gray squirrels (Sciurus carolinensis), laboratory
rabbits (Oryctologu cuniculus), ground squirrels (Marmota monax),
cattle (Bos taurus), horses (Equus ferus), domestic swine (Sus domes-
ticus), domestic chickens (Gallus domesticus), sheep (Ovis aries),
dogs (Canis familiaris), cats (Felis domesticus), cotton rats (Sig-
modon hispidus), SCID mice and nude mice (Mus  musculus) [11].
For their non-target safety trials, Knowles et al. [11] administered
an ONRAB® dose approximately 10 times greater than that needed
to vaccinate target species. Animals were monitored daily and all
tolerated exposure to the vaccine. Analyses of tissues resulted in
viral DNA detected in some lung and kidney samples. Following
histopathological analysis, the most marked findings were in the
lungs with pulmonary congestion possibly due to vaccine aspira-
tion. Oral swabs and/or fecal samples were collected from skunks,
raccoons, foxes, cotton rats, cats and dogs. Viral shedding, if any,
was generally complete by 4 days post-inoculation (dpi) except for
one skunk, which continued to shed virus in feces through 14 dpi
[11].
Our research expands on the species evaluated by Knowles et al.
[11] and investigates the vaccine as it relates to its safety in wildlife
species likely to come in contact with ONRAB® as part of WS  NRMP
ORV operations. We  investigated the effects of oral inoculation of
high titer ONRAB® vaccine in 21 eastern wild turkeys (Meleagris
gallopavo silvestri), 17 opossums (Didelphis virginiana), 14 cottontail
rabbits (Sylvilagus floridanus),  21 fox squirrels (Sciurus niger), and
15 wood rats (Neotoma spp.). We  preformed post-mortem exami-
nation to determine any gross or histological pathology that may
be linked to the vaccine. We  assessed immunogenicity of ONRAB®
in the non-target animals and evaluated the duration of viral DNA
shed into the environment via fecal and oral shedding. We  also
investigated the persistence of ONRAB DNA in select tissues of vac-
cinated animals.
2. Materials and methods
2.1. Study animals
All animals were wild caught with the exception of the eastern
wild turkeys which were purchased from a commercial breeder
(McMurry Hatchery, Webster City, IA, USA) and shipped at 2 days
old. All animal trapping, handling, maintenance, and sampling tech-
niques were approved by the WS  National Wildlife Research Center
(NWRC) Institutional Animal Care and Use Committee (QA1882).
Animals were trapped and transported under permits issued by
the State of Colorado (Permit #11TR1232A1, Permit # 12TR1232)
and individually housed throughout the study.
2.2. Vaccination
Artemis Technologies Inc. (Guelph, Ontario, Canada) supplied
us with bulk ONRAB® oral rabies vaccine under the United States
Veterinary Biological Product Permit No. VB-118764. The 50%
cell culture infectious dose (CCID50) of the vaccine was 1010.44
CCID50/mL. We  followed the methods described by Knowles [11]
et al. and orally inoculated animals with 1.8 mL  dose of vaccine,
which resulted in an infectious virus titer approximately 10 times
higher than found in a standard ONRAB® bait.
2.3. Sample collection
We  evaluated the safety of the ONRAB® vaccine via numerous
tests and observations following the methods of Knowles et al. [11].
On a daily basis we monitored animals for changes in behavior and
eating habits. We  looked for shedding of ONRAB® DNA via oral
swabs on 0, 4, and 7 days post infection (dpi) in turkeys, cotton-
tail rabbits, opossums and fox squirrels and on 0 and 4 dpi in wood
rats. We  also collected feces on 0–7, 14, 21, and 28 dpi for all species.
We collected paired blood samples on 0 and 28 dpi to evaluate sera
for Rabies virus neutralizing antibodies (rVNA).
One-half of the study animals for each species were humanly
euthanized on 4 dpi, when viral replication should be at or near
its peak [11–12,14]. The remaining individuals were euthanized
at the conclusion of the study (28 dpi). Turkeys were eutha-
nized by an intravenous injection of an overdose of barbiturates.
Opossums were anesthetized with 10 mg/kg ketamine HCl and
2 mg/kg xylazine via intramuscular injection before receiving an
intracardiac injection of an overdose of barbiturates. Cottontail
rabbits and fox squirrels were anesthetized with isoflurane then
given an overdose of barbiturates via intracardiac injection. Wood
rats were euthanized by an inhaled overdose of isoflurane.
2.4. Post-mortem examination
Following euthanasia on either 4 dpi or 28 dpi, a standard post-
mortem examination was conducted by a veterinary pathologist.
Any abnormal tissue and routine sections of lung, liver, kidney,
small intestine, and large intestine were preserved in 10% neutral
buffered formalin for histology. Tissues were embedded in paraffin,
cut at 5 m,  stained with hematoxylin and eosin stain and exam-
ined histologically. Fresh tissues were also collected for ONRAB®
DNA detection by real-time PCR.
2.5. Serological methods
Serum samples were heat inactivated at 56 ◦C for 30 min. Rabies
virus neutralizing antibodies were detected in the sera by use of the
rapid fluorescent focus inhibition test (RFFIT), as described by Smith
et al. [15]. Murine neuroblastoma cells were used for infection by
the CVS rabies virus strain. Sera with rVNA activity ≥0.2 IU/ml were
considered positive samples.
2.6. Real-time polymerase chain reaction
We  used the MagMAXTM Viral RNA isolation kit (Life Tech-
nologies, Grand Island, NY, USA), which is also recommended for
isolating DNA, to extract ONRAB® DNA from fecal and oral swabs.
The DNeasy Blood & Tissue kit (Qiagen, Valencia, California, USA)
was used to isolate DNA from 10 to 25 mg  of lung, liver, kidney,
small intestine, large intestine, and nasal turbinates as directed by
the manufacturer. Real-time PCR was  performed on the extracted
DNA using published primers and a dual-labeled probe for an
ONRAB target sequence [11]. Twenty-five milliliter PCR reactions
containing 1× TaqMan Universal Master mix  (Life Technologies,
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Table 1
The frequency of oral and fecal samples positive for ONRAB® DNA by real-time PCR, by species, following vaccination with ONRAB® .
Positive fecal swabs (na) Positive oral swabs (n)
dpi 1 2 3 4 5 6 7 14 4 7
Eastern wild turkey 14 (21) 6 (21) 1 (21) 0 (21) 0 (10) 0 (10) 0 (10) 0 (10) 1 (21) 0 (10)
Opossum 9 (17) 17 (17) 12 (14) 5 (17) 5 (17) 2 (8) 0 (8) 0 (8) 3 (17) 0 (8)
Eastern cottontail 4 (13) 0 (14) 2 (14) 0 (14) 1 (7) 0 (7) 0 (7) 0 (7) 1 (14) 0 (7)
Fox  squirrel 17 (21) 16 (21) 17 (20) 12 (21) 8 (11) 9 (11) 8 (11) 1 (11) 19 (21) 3 (11)
Wood rat 1 (15) 2 (15) 1 (15) 9 (15) – – 1 (7) 1 (7) 0 (15) –
a Sample size includes number of inoculated individuals tested.
Table 2
The frequency of tissue samples positive for ONRAB® DNA by real-time PCR, by species, following vaccination with ONRAB® .
dpi Lung (n) Liver (n) Kidney (n) Small intestine (n) Large intestine (n) Nasal turbinates (n)
Eastern wild turkey 4 2 (11) 0 (11) 0 (11) 0 (11) 4 (11)–
28  0 (10) 0 (10) 0 (10) 0 (10) 0 (10)
Opossum 4  0 (9) 0 (9) 0 (9) 0 (9) 0 (9) 0 (9)
28  0 (8) 1 (8) 1 (8) 0 (8) 0 (8) 1 (8)
Eastern cottontail 4 4 (7) 0 (7) 0 (7) 1 (7) 2 (7) 0 (7)
28  2 (7) 0 (7) 0 (7) 0 (7) 1 (7) 1 (7)
Fox  squirrel 4 9 (10) 6 (10) 8 (10) 3 (10) 5 (10) 0 (10)
28  4 (11) 1 (11) 1 (11) 0 (11) 0 (11) 1(11)
Wood rat 4 0 (8) 3 (9) 0 (9) 0 (9) 0 (9) 0 (9)
28  0 (7) 1 (7) 0 (7) 0 (7) 0 (7) 0 (7)
Grand Island, New York, USA), 400 nM forward primer, 400 nM
reverse primer, 400 nM dual-labeled probe, and 3 l DNA tem-
plate were analyzed with an ABI 7900HT real-time PCR system (Life
Technologies, Grand Island, New York) under the following condi-
tions: 50 ◦C for 2 min, 95 ◦C for 10 min  and then 45 cycles of 95 ◦C
for 10 s and 60 ◦C for 1 min. The working range of the assay was
approximately 103–108 TCID50/mL  PCR equivalents [9] and sam-
ples with cycle threshold (Ct) values less than 37 (approximately
103 TCID50/mL or greater) were considered positive for ONRAB®
DNA.
3. Results and discussion
We  did not observe any behavior changes in any of the animals
inoculated with ONRAB®. All gross and histologic lesions seen in all
species were interpreted as secondary to natural infection or exper-
imental protocol. Numerous parasites were considered incidental
findings in inoculates. Pneumonia and lymphoid hyperplasia seen
in the lungs of a single wood rat were interpreted as secondary to
aspiration and antigenic stimulation.
We  did not detect rVNA in any day 0 samples, regardless of
species (<0.06 IU/ml). We  used the RFFIT to determine that the
majority of animals (91%) responded with the induction of rVNA
from comparison of paired sera samples, sera collected at 0 and
28 dpi from the same individual. Eight of 10 inoculated turkeys
had evidence of rVNA, and all positive samples were >0.2 IU/ml. In
inoculated opossums, 8 of 8 had evidence of rVNA, and all positive
samples were >0.2 IU/ml. For the inoculated cottontail rabbits, 6 of 7
day had evidence of rVNA, and all positive samples were >0.2 IU/ml.
Eleven of 11 inoculated fox squirrels had evidence of rVNA, and
all positive samples were >17 IU/ml. Six of 8 inoculated woodrats
had evidence of rVNA, and all positive samples were >2.7 IU/ml.
These results show that nearly all animals, 91%, developed a pos-
itive rabies antibody response after being orally inoculated with
ONRAB®.
By 7 dpi no ONRAB® DNA was detected in the fecal swabs of
turkeys, opossums, or cottontails (Table 1). One wood rat and
eight fox squirrels still had detectable levels of ONRAB® DNA in
fecal swabs on 7 dpi. The high number of fox squirrels still shed-
ding ONRAB® DNA at 7 dpi was unexpected and may  be explained
by more efficient viral replication in fox squirrel cells or some
false-positive detection by PCR. Additionally, at necropsy it was
determined that at least 50% of fox squirrels were co-infected with
Leptospira interrogans [16]. This co-infection may  be a confound-
ing factor, compromising an animal’s immune system and ability
to clear the virus, resulting in the prolonged detection of ONRAB®
DNA in fecal swabs from these animals. At 14 dpi, we recovered
ONRAB® DNA from fecal swabs of one wood rat and a single fox
squirrel; by 21 dpi no ONRAB® DNA from fecal swabs was detected
in any individuals.
Oral shedding of ONRAB® DNA on 4 dpi was  only detected in
3 opossums, and one turkey and one cottontail, but nearly all fox
squirrels (Table 1). At 7 dpi, only three fox squirrels exhibited oral
shedding. With the exception of our fox squirrels, we considered
the potential persistence of ONRAB® in many non-target species
to be low given the limited ONRAB DNA recovery through both
oral and fecal sampling. Because we only tested for the presence of
ONRAB DNA, we cannot assess whether or not infectious virus was
being shed.
Although no pathology was  noted, we  detected ONRAB® DNA
in all tissue types sampled (Table 2). ONRAB® DNA was detected
most often in lung tissue, followed by liver and large intestine, kid-
ney, small intestine, and nasal turbinates. There appeared to be
some species variation as ONRAB® DNA was isolated in tissues of
14 fox squirrels, six cottontails, four turkeys, four wood rats, and
only one opossum. Although varied, our results likely show individ-
ual variation as opposed to widespread shedding and persistence
of ONRAB®.
Our results were not unexpected, and we concur with previ-
ous research [6,11,12] suggesting a low likelihood of persistence
of ONRAB® in the environment or in individual animals that con-
tact the vaccine even at ten times the recommended dose. To date
there have been no known negative impacts on target or non-target
animals following large-scale distributions of ONRAB in Canada
[12]. Based on the results of our study, ONRAB® is not expected to
have detrimental effects on non-target wildlife species if incidental
ingestion occurs following ORV campaigns in the United States.
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